Professor Ron Akehurst, BSc (Econ) (London), Hon MFPHM
Professor Akehurst is an Emeritus Professor of Health Economics at the School of Health and Related Research (ScHARR)
University of Sheffield
30 Regent Street
Sheffield S1 4DA
Tel: (+44) (0) 114 222 5446
Fax: (+44) (0) 114 272 4095
All aspects of health economics; application of microeconomic theory to problems of evaluation, production and behaviour in a health context; using economic evaluative methodology to assist health care decision making; getting more health output from the clinical research base.
My teaching interests include all aspects of Health Technology Assessment (HTA), particularly in framing HTA questions to enable the appropriate design of studies and of analysis.
Activities and Distinctions
July 2010-present. Member, Advisory Group for National Specialised Services (AGNSS)
May 2010-present. Member, Interntional Academic Council of UdG Medicine, University of Girona
March 2010-present. External Assessor, National Health & Medical Research Council (NHMRC) Centres for Research Excellence Scheme (CRE), Australia
March 2010-February 2012. Member, National Institute for Health and Clinical Excellence (NICE) Diagnostics Committee
December 2009-present. Member, Innovation Research Board (IRB), Sheffield Teaching Hospitals
February 2010-present. Member, Sheffield Quality Improvement Academy Steering Group, NHS Sheffield
June 2009-present. Honorary Member, National Institute for Health Research Faculty
Sept 2008-Dec 2011. Chair, the University Senate Budget Commitee (SBC)
2007-present. Member, NICE Methods Review Workshop
2007-present. Member, NICE Single Technology Appraisal (STA) Reference Review Group
2007-present. Visting Professor, Corvinus University, Budapest
Nov 2008-Nov 2010. Member, Research Funding Board - National Institute for Health Research (NIHR) Public Health Research Programme
2007-2008. Joint Chair, Scientific Review Committee, European Conference of International Society for Pharmaeconomics and Outcomes Research, Athens
2006-2008. Member, Scientific Committe for European Conference on Health Economics, Rome
Sept 2005-June 2006. Member, Public Health Intervention Advisory Committee for the National Institute for Health and Clinical Excellence (NICE)
Dec 2006-present. Member, Health Technology Assessment International (HTAi) Scientific Committee, Barcelona
Sept 2006-present. Member, International Health Economics Association (iHEA) Scientific Committee, Copenhagen
April 2005-present. Member of the Health Services Research Network Governing Board, elected by members category
Sept 2005–June 2006. Member, Public Health Intervention Advisory Committee for the National Institute for Clinical Excellence (NICE)
2003-present. Chair, Evidence-Based Commissioning Collaboration
2002-present. Member, University of Sheffield Academic Development Committee (ADC)
2003-2006 . Member, Organising Committee for Sixth European Conference on Health Economics, Budapest, Hungary
2003-2005 . Member, Department of Health Advisory Committee for Topic Selection (ACTS) for the National Institute for Clinical Excellence (NICE)
2003-2004 . Chair, Technology Assessment Task Force for NICE Technology Appraisals Methodology Review
2003. Member, Department of Trade and Industry (DTI) and Department of Health – NHS/Industry Partnerships Working Group (BIG T)
1999-2005. Member, NICE Appraisal Committee
1999-2003 . Non-Executive Director, then Chair/Trustee: Centre for Innovation in Primary Care, Sheffield
1998–2002 . Chair, North Trent Cancer Research Network
1996-1998 . Non-executive Director, Rotherham Health Authority
1995-1997 . Specialist Advisor to the House of Commons Health Select Committee
Corvinus University, Budapest - Honorary Professor
Publications since 2005
Llloyd A, Hodgkins P, Akehurst R, Sonuga-Barke EJS, Fitgerald P, Nixon A, Erder H, Brazier JE. Estimation of utilities in attention-deficit hyperactivity. Patient 4(4):247-57 (2011).
Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 2011, 11:404.
Madan J, Stevenson MD, Cooper KL, Ades AE, Whyte S, Akehurst R. Consistency between Direct and Indirect Trial Evidence: Is Direct Evidence Always More Reliable? Value in Health 14 (2011) 953-960.
Akehurst R, Brereton N, Ariely R, Lusa T, Groot M, Foss P, Boonen S. The cost effectiveness of Zoledronic acid 5mg for the management of postmenopausal osteoporosis in women with prioe fractures: evidence from Finland, Norway and the Netherlands. Journal of Medical Economics 2011, Vol 14 (pp53-64).
Akehurst RL. Health Technology Assessment in the United Kingdom. Value in Health 2010, Vol 13, Supplement S1 (ppS4-S5).
Brereton N, Bodger K, Kamm MA, Hodgkins P, Yan S, Akehurst R. A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective. Journal of Medical Economics 2010, Vol 13 (pp148-161).
Tappenden P, Saccardi R, Confavreux C, Sharrack B, Muraro PA, Mancardi GL, Kozak T, Farge-Bancel D, Madan J, Rafia R, Akehurst R, Snowden J. Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosi: and exploratory cost-effectiveness analysis. Bone Marrow Transplantation 2009. 305.
Stevenson MD, Macdonald MC, Langley J, Hunsche E, Akehurst R. The Cost-Effectiveness of Bosentan in the United Kingdom for Patients with Pulmonary Arterial Hypertension of WHO Functional Class III. Value in Health. Vol 12 (8): 1100-1105.
Karnon J, Tolley K, Oyee J, Ossa D, Akehurst R. Cost-utility analysis of deferasirox compared to standard therapy with desferriozamine for patients requiring iron chelation therapy in the United Kingdom. Current Medical Research and Opinion 2008, Vol 24(6): 1609-1621.
Nagy B, Brennan A, Brandtmuller A, Thomas S, Gallagher M, Sullivan S, Akehurst R. Introducing a methodology to use activities of daily living outcomes in the assessment of the cost-effectiveness of Alzheimer's disease treatments: A case study using rivastigmine patch. Alzheimer's and Dementia 2008. Vol 4(4): 455-455.
Sutcliffe P, Dixon S, Akehurst R, Wilkinson A, Shippam A, White S, Richards R, Caddy C. Evaluation of core surgical procedures for sex reassignment in male-to-female and female-to-male transexuals: a systematic review. Journal of Plastic, Reconstructive and Aesthetic Surgery 2008. Vol 62(3): 294-306.
Kaltenthaler E, Tappenden P, Booth A, Akehurst R. Comparing methods for full versus single technology apprasial: A case study of docetaxel and paclitaxel for early breast cancer. Health Policy 87 2008; 389-400.
Karnon J, Brennan A, Akehurst R. A Critique and Impact Analysis of Decision Modelling Assumptions. Medical Decision Making 2007, Vol 27(4):491-499.
Culyer AJ, McCabe C, Briggs AH, Claxton K, Buxton M, Akehurst R, Sculpher M, Brazier J. Searching for a threshold, not setting one: the role of the National Institute of Health and Clinical Excellence, Journal of Health Services Research and Policy; 12(1) January 2007: 56-58(3).
Brazier J, Akehurst R, Brennan A, Dolan P, Claxton K, McCabe C, Sculpher M, Tsuchyia A Should patients have a greater role in valuing health states? Applied Health Economics and Policy 2005; 4(4): 201-208.
Brennan A, Akehurst R, Davis S, Sakai H, Abbott V (2007). The Cost-Effectiveness of Lanthanum Carbonate in the Treatment of Hyperphosphatemia in Patients with End-Stage Renal Disease, Value in Health; 10 (1): 32-41.
Karnon J, Bakhai A, Brennan A, Flather M, Warren E, Gray D, Akehurst R. A cost-utility analysis of clopidogrel in patients with non-ST-segment-elevation acute coronary syndromes in the UK, International Journal of Cardiology; 109(3):307-16.
Claxton K, Sculpher M, Culyer A, McCabe C, Briggs A, Akehurst R, Buxton M, Brazier J. Discounting and cost-effectiveness in NICE - stepping back to sort out a confusion, Health Economics 2006; 15(1): 1-4.
O´Hagan A, McCabe C, Akehurst R, Brennan A, Briggs A, Claxton K, Fenwick E, Fryback D, Sculpher M, Spiegelhalter D, and Willan A. Incorporation of uncertainty in health economic modelling studies. PharmacoEconomics 2005; 23 (6): 529-536.
Claxton K, Sculpher M, McCabe C, Briggs A, Akehurst R, Buxton M, Brazier J, O´Hagan A. Probabilistic Sensitivity Analysis for NICE Technology Assessment: Not an Optional Extra. Health Economics 2005; 14(4): 339-347.
Karnon J, Brennan, A, Pandor A, Fowkes G, Lee A, Gray D, Coshall C, Nicholls C, Akehurst R. Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK, Current Medical Research and Opinion, 2005; 21(1):101-12.
Ron Akehurst is based in Health Economics and Decision Science (HEDS)